These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
180 related items for PubMed ID: 8680026
1. Micronucleus frequency in peripheral blood lymphocytes from patients with systemic lupus erythematosus. Severin E. Rom J Morphol Embryol; 1995; 41(1-2):55-8. PubMed ID: 8680026 [Abstract] [Full Text] [Related]
2. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status. Aceves Avila FJ, Esquivel Nava GA, Gallegos Arreola MP, Gómez Meda B, Zúñiga González G, Ramos-Remus C. J Rheumatol; 2004 Jul; 31(7):1335-9. PubMed ID: 15229952 [Abstract] [Full Text] [Related]
3. [Chromosomal aberrations in lymphocytes of patients with systemic lupus erythematosus during cytostatic therapy]. Latipova NS, Aliavi AL. Ter Arkh; 2002 Jul; 74(5):35-8. PubMed ID: 12087903 [Abstract] [Full Text] [Related]
4. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Manger K, Wildt L, Kalden JR, Manger B. Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968 [Abstract] [Full Text] [Related]
5. Micronucleus frequency in women with genital Chlamydia Trachomatis infection before and after therapy. Dimitrijević A, Milosević-Djordjević O, Grujicić D, Arsenijević S. Mutat Res; 2006 Sep 19; 608(1):43-8. PubMed ID: 16777475 [Abstract] [Full Text] [Related]
6. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. J Rheumatol; 2002 Feb 19; 29(2):282-7. PubMed ID: 11838845 [Abstract] [Full Text] [Related]
7. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Arthritis Rheum; 2005 Jun 19; 52(6):1676-83. PubMed ID: 15934077 [Abstract] [Full Text] [Related]
8. Intravenous cyclophosphamide for lupus nephritis in Thai children. Vachvanichsanong P, Dissaneewate P, Winn T. Scand J Rheumatol; 2004 Jun 19; 33(5):339-42. PubMed ID: 15513684 [Abstract] [Full Text] [Related]
9. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K. Arthritis Rheum; 2005 Oct 19; 52(10):3168-74. PubMed ID: 16200620 [Abstract] [Full Text] [Related]
10. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Petri M, Jones RJ, Brodsky RA. Arthritis Rheum; 2003 Jan 19; 48(1):166-73. PubMed ID: 12528116 [Abstract] [Full Text] [Related]
11. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE. J Rheumatol; 1992 Oct 19; 19(10):1625-7. PubMed ID: 1464880 [Abstract] [Full Text] [Related]
12. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM. J Rheumatol; 2008 Sep 19; 35(9):1768-75. PubMed ID: 18634157 [Abstract] [Full Text] [Related]
13. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Mok CC, Lau CS, Wong RW. Arthritis Rheum; 1998 May 19; 41(5):831-7. PubMed ID: 9588734 [Abstract] [Full Text] [Related]
14. Immunosuppressive drug therapy of systemic lupus erythematosus. Fox DA, McCune WJ. Rheum Dis Clin North Am; 1994 Feb 19; 20(1):265-99. PubMed ID: 8153402 [Abstract] [Full Text] [Related]
15. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE. Ann Rheum Dis; 2008 Jan 19; 67(1):74-9. PubMed ID: 17545189 [Abstract] [Full Text] [Related]
16. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. J Rheumatol; 2003 Mar 19; 30(3):480-4. PubMed ID: 12610805 [Abstract] [Full Text] [Related]
17. An open study of B lymphocyte depletion in systemic lupus erythematosus. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. Arthritis Rheum; 2002 Oct 19; 46(10):2673-7. PubMed ID: 12384926 [Abstract] [Full Text] [Related]
18. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics. Tao J, Dong J, Li Y, Liu YQ, Yang J, Wu Y, Li L, Shen GX, Tan ZJ, Tu YT. J Eur Acad Dermatol Venereol; 2009 Apr 19; 23(4):433-7. PubMed ID: 19335730 [Abstract] [Full Text] [Related]
19. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy]. Yang XY, Zhu X, Liang LQ, Zhan ZP, Ye YJ. Zhonghua Yi Xue Za Zhi; 2005 Apr 13; 85(14):960-2. PubMed ID: 16061002 [Abstract] [Full Text] [Related]
20. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus]. Stanislav ML, Balabanova RM, Nikonova MF, Litvina MM, Iarilin AA. Ter Arkh; 2000 Apr 13; 72(5):44-9. PubMed ID: 11109620 [Abstract] [Full Text] [Related] Page: [Next] [New Search]